News Conference News ESC 2025 ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation Todd Neale September 08, 2025
News Conference News ESC 2025 Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes Todd Neale September 08, 2025
News Conference News ESC 2025 AMALFI: Modest AF Detection With ECG Patch Screening Michael O'Riordan September 05, 2025
News Conference News ESC 2025 DAPT’s Role After CABG Questioned: TACSI and TOP-CABG Caitlin E. Cox September 05, 2025
News Conference News ESC 2025 HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients Caitlin E. Cox September 01, 2025
News Conference News ESC 2025 AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC Todd Neale September 01, 2025
News Daily News Frail Older Patients With AF May Fare Better Switching to DOAC Todd Neale August 05, 2025
News Daily News POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies L.A. McKeown July 15, 2025
News Daily News No Clear Risk of Dementia After TIA: Framingham Heart Study L.A. McKeown July 10, 2025
News Conference News NY Valves 2025 No Benefit of Sentinel Device During TAVI: Updated Meta-analysis Todd Neale July 04, 2025
News Daily News Low Bleeding Risk With Abelacimab in AF Patients Undergoing Invasive Procedures Todd Neale June 10, 2025
News Conference News ESOC 2025 High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants Todd Neale May 29, 2025
News Daily News Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding L.A. McKeown May 16, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for March 2025 Caitlin E. Cox April 01, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025
Presentation ACC 2025 Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study Presenter: Isabelle Mahé March 29, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025